Tumor growth in the HER2-LsbMDDs treatment group was significantly suppressed as compared to those of Tynen® (p < .05 on day 21), the LsbMDDs alone (p < .001 on day 21), and the negative control of the DNS-LsbMDDs (p < .05 on day 21). The gene discussed is ERBB2; the disease is neoplasm.